Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Haug

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The British Journal of Dermatology|September 18, 2018
Programmed death-1 blockade for multiple basal cell carcinomas: clearing the field systemically?V Haug, B Schilling
RSC Advances|August 27, 2025
Molecular fluctuations in mixed-metal MOF-74: influence of the metal compositionArda Yildirim, Tabea C V Haug, Michael Fröba, et al.
The British Journal of Dermatology|May 15, 2018
Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinomaV Haug, V Behle, S Benoit, et al.
Diseases of the Colon and Rectum|October 1, 1996
Functional results after transanal endoscopic microsurgeryM E Kreis, E C Jehle, V Haug, et al.
Burns : Journal of the International Society for Burn Injuries|August 26, 2020
Influence of burn severity on endothelial glycocalyx shedding following thermal trauma: A prospective observational studyC Tapking, J F Hernekamp, J Horter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 10, 2011
Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderlyK Fritsch, B Kasenda, C Hader, et al.
Burns : Journal of the International Society for Burn Injuries|February 21, 2024
Use of the modified meek technique for the coverage of extensive burn woundsC Tapking, A Panayi, V Haug, et al.
Clinical Genetics|October 29, 2008
Refining the phenotype of alpha-1a Tubulin (TUBA1A) mutation in patients with classical lissencephalyD J Morris-Rosendahl, J Najm, A M A Lachmeijer, et al.
Molecular Pharmacology|March 5, 2011
Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitorTerrance D Barrett, Heather L Palomino, Theresa I Brondstetter, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The British Journal of Dermatology|September 18, 2018
Programmed death-1 blockade for multiple basal cell carcinomas: clearing the field systemically?V Haug, B Schilling
RSC Advances|August 27, 2025
Molecular fluctuations in mixed-metal MOF-74: influence of the metal compositionArda Yildirim, Tabea C V Haug, Michael Fröba, et al.
The British Journal of Dermatology|May 15, 2018
Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinomaV Haug, V Behle, S Benoit, et al.
Diseases of the Colon and Rectum|October 1, 1996
Functional results after transanal endoscopic microsurgeryM E Kreis, E C Jehle, V Haug, et al.
Burns : Journal of the International Society for Burn Injuries|August 26, 2020
Influence of burn severity on endothelial glycocalyx shedding following thermal trauma: A prospective observational studyC Tapking, J F Hernekamp, J Horter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 10, 2011
Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderlyK Fritsch, B Kasenda, C Hader, et al.
Burns : Journal of the International Society for Burn Injuries|February 21, 2024
Use of the modified meek technique for the coverage of extensive burn woundsC Tapking, A Panayi, V Haug, et al.
Clinical Genetics|October 29, 2008
Refining the phenotype of alpha-1a Tubulin (TUBA1A) mutation in patients with classical lissencephalyD J Morris-Rosendahl, J Najm, A M A Lachmeijer, et al.
Molecular Pharmacology|March 5, 2011
Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitorTerrance D Barrett, Heather L Palomino, Theresa I Brondstetter, et al.
Pageof 1